Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts

Future Medicinal Chemistry

Volumn 7, Issue 4, 2015, Pages 437-448

  Maggiolini, Marcello ^a   Santolla, Maria Francesca ^a   Avino, Silvia ^a   Aiello, Francesca ^a   Rosano, Camillo ^b   Garofalo, Antonio ^a   Grande, Fedora ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,5 TRIMETHOXY N (4 OXO 4H BENZO[B]PYRROLO[1,2 D][1,4]OXAZIN 7 YL)BENZAMIDE; 7 (QUINOXALIN 2 YLAMINO) 4H BENZO[B]PYRROLO[1,2 D][1,4]OXAZIN 4 ONE; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR ANTAGONIST; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ANTAGONIST; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; G PROTEIN COUPLED RECEPTOR; LIGAND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; BREAST CANCER; BREAST CANCER CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG COMPETITION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING ASSAY; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL MOTION; CHEMICAL STRUCTURE; CONFORMATION; DRUG EFFECTS; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL LINE;

BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDICATORS AND REAGENTS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PYRROLES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84928168009     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.3     Document Type: Article

References (33)

1. Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest. 116, 561-570 (2006).
2. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J. Endocrinol. 204, 105-114 (2010).
3. Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR. Estrogen-induced activation Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor throughout release of HB-EGF. Mol. Endocrinol. 14, 1649-1660 (2000).
4. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell. Endocrinol. 308, 32-38 (2009).
5. Bologa CG, Revankar CM, Young SM et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2, 207-212 (2006).
6. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: a transmembrane estrogen receptor. J. Steroid Biochem. Mol. Biol. 109, 350-353 (2008).
7. Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol. 7, 715-726 (2011).
8. Hammond R, Mauk R, Ninaci D, Nelson D, Gibbs RB. Chronic treatment with estrogen receptor agonists restores acquisition of a spatial learning task in young ovariectomized rats. Horm. Behav. 56, 309-314 (2009).
9. Blasko E, Haskell CA, Leung S et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J. Neuroimmunol. 214, 67-77 (2009).
10. Arterburn JB, Oprea TI, Prossnitz ER, Edwards BS, Sklar LA. Discovery of selective probes and antagonists for G protein-coupled receptors for FPR/FPRL1 and GPR30. Curr. Top. Med. Chem. 9, 1227-1236 (2009).
11. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2. Lewis rats. Endocrinology 150, 3753-3758 (2009).
12. Lappano R, Rosano C, Santolla MF et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr. Cancer Drug Targ. 12, 531-542 (2012).
13. Santolla MF, De Francesco EM, Lappano R, Rosano C, Abonante S, Maggiolini, M. Niacin activates the G protein-coupled estrogen receptor (GPER)-mediated signaling. Cell. Signal. 26(7), 1466-1475 (2014).
14. Dennis MK, Field AS, Burai R et al. Identification of GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J. Steroid Biochem. Mol. Biol. 127, 358-366 (2011).
15. Huryn DM, Resnick LO, Wipf P. Contributions of academic laboratories to the discovery and development of chemical biology tools. J. Med. Chem. 56, 7161-7176 (2013).
16. Burai R, Ramesh C, Nayak TK et al. Synthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30. PLoS ONE 7, e46861 (2012).
17. Lappano R, Santolla MF, Pupo M et al. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Breast Cancer Res. 14, R12 (2012).
18. Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130, 1091-1103 (2008).
19. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993).
20. Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, Maggiolin M. Recent advances in the rationale design of GPER ligands. Curr. Med. Chem. 19, 6199-6206 (2012).
21. Murshudov GN, Skubák P, Lebedev AA et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355-367 (2011).
22. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell Endocrinol. 204, 105-114 (2010).
23. Chimento A, Casaburi I, Bartucci M et al. Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells. Cell Death Dis. 4, e747 (2013).
24. Amaro AA, Esposito AI, Mirisola V et al. Endocrine disruptor agent nonyl phenol exerts an estrogen-like transcriptional activity on estrogen receptor positive breast cancer cells. Curr. Med. Chem. 21, 630-640 (2014).
25. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
26. Lappano R, Recchia AG, De Francesco EM et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 6, e16631 (2011).
27. Jirkovsky I, Humber LG, Baudy R. 4-Substituted-4Hpyrrolo[2,1-c][1,4]benzoxazines. J. Heterocyclic Chem. 13, 311-316 (1976).
28. Lancelot J-C, Rault S, Laduree D, Robba M. Pyrido[3,2-e] pyrrolo[1,2-a]pyrazines. Chem. Pharm. Bull. 33, 2798-2802 (1985).
29. 3 for conversion of nitroarenes to primary amines. Synthetic Commun. 25, 3799-3803 (1995).
30. Dennis MK, Burai R, Ramesh C et al. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 5, 421-427 (2009)..
31. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 15, 97-101 (2005).
32. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337 (2004).
33. Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast carcinoma. Endocr. J. 56, 1-7 (2009).